Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on May 2, 2014, involving Dr. P J T Vallance under the GSK Deferred Annual Bonus Plan:
- Exercise of a nil-priced option over 17,569 shares and 6,993 shares granted on February 24, 2011.
- Both tranches vested on February 24, 2014.
- GlaxoSmithKline delivered the net-of-tax value in shares, totaling 13,017 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the total number of shares issued to Dr. P J T Vallance (13,017) following the net-of-tax settlement.
- Confirm the vesting date of the underlying options (February 24, 2014) versus the transaction notification date (May 2, 2014).
- Review the specific terms of the GSK Deferred Annual Bonus Plan regarding nil-priced options.